VEGFA and myelodysplastic syndrome: It has been reported that a derivative of the geldanamycin, 17-N-allylamino-17-demethoxy geldanamycin (17-AAG), one of the original and most studied heat shock protein 90 (HSP90) inhibitors, can reduce the abnormal VEGF expression produced by the stromal cells from children with MDS by blocking the ability of the MDS stromal cells to stimulate the growth of leukemic subtypes [69].